Neuraminidase Amino Acid Sequences of Influenza A/H3N2 and B Viruses Isolated from Influenza Patients in the 2014/15 Japanese Influenza Season.

Background Neuraminidase (NA) is a surface protein essential for influenza virus replication. NA inhibitors are commonly used for the treatment of influenza patients in Japan. Several mutations that reduce the effect of NA inhibitors have been reported. We sequenced the whole NA segment of isolated virus from influenza patients and investigated the relation between the NA amino acid sequence and the 50％ inhibitory concentration (IC_50) of four NA inhibitors. Materials and Methods Forty A/H3N2 and 19 B influenza virus isolated from patients in the 2014/15 influenza season were analyzed. The IC_50 was determined by a neuraminidase inhibition assay using a fluorescent substrate. Viral RNA was amplified by RT-PCR and the genome was sequenced using a next generation sequencer. The deduced amino acid sequences were analyzed. Results There was no AA change in the NA catalytic site of the A/H3N2 and B viruses isolated in the 2014-15 influenza season. There was no significant relation between the NA amino acids and the IC_50 of the four NA inhibitors for A/H3N2 or B viruses. Conclusion The catalytic site of NA was highly conserved for these A/H3N2 and B viruses. No emergence of NA amino acid mutations related to the sensitivity of the four currently used NA inhibitors was observed.

[1]  H. Ikematsu,et al.  In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  S. Maurer-Stroh,et al.  Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility. , 2015, The Journal of antimicrobial chemotherapy.

[3]  Dayan Wang,et al.  Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014 , 2015, Antiviral research.

[4]  M. Kiso,et al.  Characterization of a Large Cluster of Influenza A(H1N1)pdm09 Viruses Cross-Resistant to Oseltamivir and Peramivir during the 2013-2014 Influenza Season in Japan , 2015, Antimicrobial Agents and Chemotherapy.

[5]  Timothy B. Stockwell,et al.  Universal Influenza B Virus Genomic Amplification Facilitates Sequencing, Diagnostics, and Reverse Genetics , 2014, Journal of Clinical Microbiology.

[6]  T. Lam,et al.  Comparison of Mutation Patterns in Full-Genome A/H3N2 Influenza Sequences Obtained Directly from Clinical Samples and the Same Samples after a Single MDCK Passage , 2013, PloS one.

[7]  A. Kelso,et al.  Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. , 2011, The New England journal of medicine.

[8]  S. Kashiwagi,et al.  Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. , 2009, The Journal of infection.

[9]  Yoshihiro Kawaoka,et al.  Single-Reaction Genomic Amplification Accelerates Sequencing and Vaccine Production for Classical and Swine Origin Human Influenza A Viruses , 2009, Journal of Virology.

[10]  Larisa V. Gubareva,et al.  Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.

[11]  C Oseroff,et al.  Human memory CTL response specific for influenza A virus is broad and multispecific. , 2000, Human immunology.

[12]  Y. Kanegae,et al.  Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season , 1990, Journal of virology.

[13]  A. Kendal,et al.  Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. , 1990, Virology.

[14]  G. Air,et al.  Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. , 1985, Virology.

[15]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[16]  S. Kashiwagi,et al.  In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  S. Kashiwagi,et al.  In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[18]  S. Kashiwagi,et al.  In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010–2011 season in Japan , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.